Nautilus Biotechnology Inc (NAUT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $295.50M
Last updated: Nov 17, 2026 at 4:43 PM ET
Nautilus Biotechnology Inc (NAUT) Statistics
Nautilus Biotechnology (NAUT) has a market cap of $295.50M and an enterprise value of $285.04M. It kept -13816.75% of revenue as net income over the last 12 months. Revenue fell 95.58% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 3.54% below the market cap, as cash exceeds debt.
| Market Cap | $295.50M |
|---|---|
| Enterprise Value | $285.04M |
| Latest price (Nov 17, 2026) | $2.36 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 27, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 708.2x and 2.6x.
| P/S Ratio | 708.2x |
|---|---|
| Forward P/S | 442.0x |
| P/B Ratio | 2.6x |
Price Statistics
The stock is up 31.11% over 52 weeks and trades 22.92% above its 50-day average.
| Beta (1Y) | 1.55 |
|---|---|
| 52-Week Change | +31.11% |
| 1-Month Change | -10.27% |
| 3-Month Change | +161.79% |
| 6-Month Change | -0.84% |
| 5-Year Change | -48.88% |
| Total Return (1Y) | +31.11% |
| Total Return (3Y CAGR) | -8.29% |
| Total Return (5Y CAGR) | -14.16% |
| Return vs SPY (1Y) | -4.77% |
| Max Drawdown (1Y) | -78.44% |
| Max Drawdown (3Y) | -81.15% |
| Sharpe Ratio (1Y) | 0.06 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $1.92 |
| 200-Day Average | $2.13 |
| 52-Week Range | $0.84 to $4.31 |
| RSI (14 Days) | 51.6 |
| Average Volume (20 Days) | 7.63M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.25x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.25x |
|---|---|
| Quick Ratio | 9.25x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -50.26% over the last 12 months, against a 5-year average of -25.54%.
| Return on Equity (ROE) | -50.26% |
|---|---|
| Return on Assets (ROA) | -39.34% |
| ROE (5Y Average) | -25.54% |
| ROA (5Y Average) | -22.01% |
| ROIC (5Y Average) | -33.65% |
| Asset Turnover | 0.00x |
Scores
NAUT has an Altman Z-Score of 1.25, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.25 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $424.00K over the last 12 months.
| Revenue | $424.00K |
|---|---|
| Revenue Growth (YoY) | -95.58% |
| Gross Profit | -$1.20M |
| Operating Income | -$64.05M |
| Pretax Income | -$58.58M |
| Net Income | -$58.58M |
| EBITDA | -$56.89M |
| Reported EPS (TTM) | -$0.46 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 78.27% of the $148.92M in total assets.
| Cash and Equivalents | $10.47M |
|---|---|
| Total Debt | $0 |
| Net Cash | $10.47M |
| Net Cash Per Share | $0.08 |
| Working Capital | $80.48M |
| Shareholder Equity | $116.56M |
| Book Value Per Share | $0.92 |
| Total Assets | $148.92M |
| Total Liabilities | $32.37M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.65M of capital spending, operating cash flow left -$55.13M of free cash flow.
| Operating Cash Flow | -$52.48M |
|---|---|
| Capital Expenditures | $2.65M |
| Free Cash Flow | -$55.13M |
| FCF Per Share | -$0.43 |
| Depreciation and Amortization | $5.62M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -15105.66%.
| Gross Margin | -283.73% |
|---|---|
| Operating Margin | -15105.66% |
| Pretax Margin | -13816.75% |
| Net Margin | -13816.75% |
| EBITDA Margin | -13417.22% |
| FCF Margin | -13003.54% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -23.48% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -23.48% |
Dividends and Yields
NAUT does not pay a dividend. Its free cash flow yield is -18.36%.
| FCF Yield | -18.36% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 6 similar companies, NAUT has the highest P/S.
P/S RatioPeer median 4.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -4.59%
| P/S Ratio | 708.2x vs 4.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -95.58% vs -4.59% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NAUT
What is NAUT's market cap?
Nautilus Biotechnology has a market cap of $295.50M. Its enterprise value, which adds debt and subtracts cash, is $285.04M.
How many shares of NAUT are outstanding?
Nautilus Biotechnology has 127.24M shares outstanding. The count is up 0.74% from a year earlier.
Does NAUT pay a dividend?
No. Nautilus Biotechnology does not pay a dividend.
How much debt does NAUT have?
Nautilus Biotechnology has $0 of total debt and $10.47M of cash and equivalents, a net cash position of $10.47M.
NAUT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors